India’s pharmaceutical companies USV Private Ltd., Scimplify, Nephroplus, Glenmark and Shilpa Medicare have expressed interest in locating in an economic zone to avail of fiscal incentives, according to Tereso Panga, director-general of the Philippine Economic Zone Authority (PEZA).
In a statement, Panga said these companies are eyeing investments in packaging, active pharmaceutical ingredient (API) and small molecules formulation, pharma logistics, and healthcare services.
Panga reported this as one of the outcomes of the mission recently conducted by PEZA in cooperation with HSBC to India where it has arranged business scoping meetings with leading pharmaceutical companies many of which are already engaged in the importation and local distribution of APIs and patented biosimilars, biologics, and other generic ethical as well as over-the-counter medicines.
PEZA is promoting the establishment of pharmaceutical manufacturing ecozones (pharma zones) and is working with other government agencies and pharmaceutical industry associations in setting the standards and requirements governing the establishment and registration of pharma zones in the country.
To jumpstart the pharma zone project, PEZA will sign today a memorandum of agreement with the Food and Drug Administration (FDA) for the electronic and green lane facilitation of registered business enterprises’ applications for permits for license to operate, good manufacturing practices and import and export.
PEZA will also sign the registration agreement with Victoria Industrial Park in Victoria, Tarlac as a pharmazone that will host an FDA laboratory.
Mumbai-based USV India is one of the oldest and most established pharmaceutical companies providing API, peptides, biosimilars, injectables and ophthalmics and solid orals.
Scimplify is an end-to-end contract development and manufacturing organization that helps pharma and chemical companies deliver innovative products.
NephroPlus is Asia’s largest dialysis network with more than 400 clinics.
Glenmark Pharmaceuticals is a research”led, global pharmaceutical company, having a presence across branded, generics, and OTC segments; with a focus in the therapy areas of respiratory, dermatology and oncology.
